ConductScience.org, home

Trial · NCT01902290

Outcomes15

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYChange From Baseline in Asthma Control Questionnaire (ACQ) Composite Score at Week 24Baseline and week 24Full analysis set with available datascore on a scaleLEAST_SQUARES_MEAN
SECONDARYAsthma Exacerbation RateBaseline to week 24Full analysis set with available dataexacerbations per subject-yearNUMBER
SECONDARYChange From Baseline in ACQ Composite Score at Week 24 in ICS+LABA SubpopulationBaseline and week 24Full analysis set participants who were taking both inhaled corticosteroids (ICS) and a long-acting β-agonist (LABA) at baseline with available data.score on a scaleLEAST_SQUARES_MEAN
SECONDARYAsthma Exacerbation Rate in ICS+LABA SubpopulationBaseline to week 24Full analysis set participants taking both ICS and LABA at baseline with available dataexacerbations per subject-yearNUMBER
SECONDARYChange From Baseline in Daily Asthma Symptom Score (7-day Average Score)Baseline and week 24Full analysis set with available datascore on a scaleLEAST_SQUARES_MEAN
SECONDARYChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)Baseline and week 24Full analysis set with available dataL/sLEAST_SQUARES_MEAN
SECONDARYChange From Baseline in Daily Rescue Short-acting Beta-agonist UseBaseline and week 24Full analysis set with available datapuffsLEAST_SQUARES_MEAN
SECONDARYTime to First Asthma ExacerbationFrom first dose of study drug to week 24Full analysis set with available datapercentage of participantsNUMBER
SECONDARYNumber of Participants Who Experienced an Asthma ExacerbationBaseline to week 24Full analysis set with available dataParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYChange From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Overall ScoreBaseline and week 24Full analysis set with available datascore on a scaleLEAST_SQUARES_MEAN
SECONDARYChange From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEFR)Baseline and week 24Full analysis set with available dataL/minLEAST_SQUARES_MEAN
SECONDARYChange From Baseline in Variation of Peak FlowBaseline and week 24Full analysis set with available dataL/minLEAST_SQUARES_MEAN
SECONDARYProportion of Asthma Symptom-free Days in 4-weeks Intervals Over the Treatment PeriodBaseline (the 4 weeks prior to first dose) and 4-week intervals up to week 24Full analysis set with available data during each 4-week intervalproportion of daysMEAN
SECONDARYSerum Brodalumab ConcentrationDay 1 and weeks 1, 2, 4, 8, 12, 16, and 22 at predose, week 2 + 3 days, week 22 + 3, 7, 10, and 14 daysParticipants who received brodalumab with available concentration data at each time point.µg/mLMEAN
OTHER_PRE_SPECIFIEDNumber of Participants With Treatment-emergent Adverse Events (TEAEs)From first dose of study drug up to the end of study, 28 weeksRandomized participants who received at least 1 dose of study drug.ParticipantsCOUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01902290/outcomes